Research programme: neurological disorders - Biohaven Pharmaceutical Holding CompanyAlternative Names: BHV 3000; BHV-3500
Latest Information Update: 17 Feb 2017
At a glance
- Originator Undisclosed
- Developer Biohaven Pharmaceutical Holding Company
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Research Neurological disorders
Most Recent Events
- 16 Feb 2017 Early research in Neurological disorders in United Kingdom (unspecified route)